US 11,505,604 B2Granted

Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer

AssigneePrecision Biologics, Inc.

InventorsXue-Ping Wang, Philip M. Arlen

Life of this patent

Estimating the term…

Abstract

This invention relates to humanized antibodies that selectively bind the 31.1 epitope on the A33 protein differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages.

Claims20

Dependent claims

An isolated nucleic acid that encodes an antibody or fragment thereof that binds to an A33 antigen, wherein said antibody or fragment thereof comprises:

a) a heavy chain comprising the variable chain of antibody cdr31.1-HC comprising amino acids 1 to 118 of SEQ ID NO:74 and a light chain comprising the variable light chain of antibody cdr31.1-LC comprising amino acids 1 to 107 of SEQ ID NO:84;
b) a heavy chain comprising the variable chain of antibody cdr31.1-HC comprising amino acids 1 to 118 of SEQ ID NO:74 and a light chain comprising the variable light chain of antibody abb31.1-LC comprising amino acids 1 to 107 of SEQ ID NO:85;
c) a heavy chain comprising the variable chain of antibody cdr31.1-HC comprising amino acids 1 to 118 of SEQ ID NO:74 and a light chain comprising the variable light chain of antibody sdr31.1-LC comprising amino acids 1 to 107 of SEQ ID NO:86;
d) a heavy chain comprising the variable chain of antibody cdr31.1-HC comprising amino acids 1 to 118 of SEQ ID NO:74 and a light chain comprising the variable light chain of antibody ven31.1-LC comprising amino acids 1 to 107 of SEQ ID NO:87;
e) a heavy chain comprising the variable chain of antibody abb31.1-HC comprising amino acids 1 to 118 of SEQ ID NO:75 and a light chain comprising the variable light chain of antibody cdr31.1-LC comprising amino acids 1 to 107 of SEQ ID NO:84;
f) a heavy chain comprising the variable chain of antibody abb31.1-HC comprising amino acids 1 to 118 of SEQ ID NO:75 and a light chain comprising the variable light chain of antibody abb31.1-LC comprising amino acids 1 to 107 of SEQ ID NO:85;
g) a heavy chain comprising the variable chain of antibody abb31.1-HC comprising amino acids 1 to 118 of SEQ ID NO:75 and a light chain comprising the variable light chain of antibody sdr31.1-LC comprising amino acids 1 to 107 of SEQ ID NO:86;
h) a heavy chain comprising the variable chain of antibody abb31.1-HC comprising amino acids 1 to 118 of SEQ ID NO:75 and a light chain comprising the variable light chain of antibody ven31.1-LC comprising amino acids 1 to 107 of SEQ ID NO:87;
i) a heavy chain comprising the variable chain of antibody sdr31.1-HC comprising amino acids 1 to 118 of SEQ ID NO:76 and a light chain comprising the variable light chain of antibody cdr31.1-LC comprising amino acids 1 to 107 of SEQ ID NO:84;
j) a heavy chain comprising the variable chain of antibody sdr31.1-HC comprising amino acids 1 to 118 of SEQ ID NO:76 and a light chain comprising the variable light chain of antibody abb31.1-LC comprising amino acids 1 to 107 of SEQ ID NO:85;
k) a heavy chain comprising the variable chain of antibody sdr31.1-HC comprising amino acids 1 to 118 of SEQ ID NO:76 and a light chain comprising the variable light chain of antibody sdr31.1-LC comprising amino acids 1 to 107 of SEQ ID NO:86;
l) a heavy chain comprising the variable chain of antibody sdr31.1-HC comprising amino acids 1 to 118 of SEQ ID NO:76 and a light chain comprising the variable light chain of antibody ven31.1-LC comprising amino acids 1 to 107 of SEQ ID NO:87;
m) a heavy chain comprising the variable chain of antibody ven31.1-HC comprising amino acids 1 to 118 of SEQ ID NO:77 and a light chain comprising the variable light chain of antibody cdr31.1-LC comprising amino acids 1 to 107 of SEQ ID NO:84;
n) a heavy chain comprising the variable chain of antibody ven31.1-HC comprising amino acids 1 to 118 of SEQ ID NO:77 and a light chain comprising the variable light chain of antibody abb31.1-LC comprising amino acids 1 to 107 of SEQ ID NO:85;
o) a heavy chain comprising the variable chain of antibody ven31.1-HC comprising amino acids 1 to 118 of SEQ ID NO:77 and a light chain comprising the variable light chain of antibody sdr31.1-LC comprising amino acids 1 to 107 of SEQ ID NO:86;
p) a heavy chain comprising the variable chain of antibody ven31.1-HC comprising amino acids 1 to 118 of SEQ ID NO:77 and a light chain comprising the variable light chain of antibody ven31.1-LC comprising amino acids 1 to 107 of SEQ ID NO:87;
q) a heavy chain polypeptide of antibody cdr31.1-HC SEQ ID NO:74 and a light chain polypeptide of antibody cdr31.1-LC SEQ ID NO:84;
r) a heavy chain polypeptide of antibody cdr31.1-HC SEQ ID NO:74 and a light chain polypeptide of antibody abb31.1-LC SEQ ID NO:85;
s) a heavy chain polypeptide of antibody cdr31.1-HC SEQ ID NO:74 and a light chain polypeptide of antibody sdr31.1-LC SEQ ID NO:86;
t) a heavy chain polypeptide of antibody cdr31.1-HC SEQ ID NO:74 and a light chain polypeptide of antibody ven31.1-LC SEQ ID NO:87;
u) a heavy chain polypeptide of antibody abb31.1-HC SEQ ID NO:75 and a light chain polypeptide of antibody cdr31.1-LC SEQ ID NO:84;
v) a heavy chain polypeptide of antibody abb31.1-HC SEQ ID NO:75 and a light chain polypeptide of antibody abb31.1-LC SEQ ID NO:85;
w) a heavy chain polypeptide of antibody abb31.1-HC SEQ ID NO:75 and a light chain polypeptide of antibody sdr31.1-LC SEQ ID NO:86;
x) a heavy chain polypeptide of antibody abb31.1-HC SEQ ID NO:75 and a light chain polypeptide of antibody ven31.1-LC SEQ ID NO:87;
y) a heavy chain polypeptide of antibody sdr31.1-HC SEQ ID NO:76 and a light chain polypeptide of antibody cdr31.1-LC SEQ ID NO:84;
z) a heavy chain polypeptide of antibody sdr31.1-HC SEQ ID NO:76 and a light chain polypeptide of antibody abb31.1-LC SEQ ID NO:85;
aa) a heavy chain polypeptide of antibody sdr31.1-HC SEQ ID NO:76 and a light chain polypeptide of antibody sdr31.1-LC SEQ ID NO:86;
bb) a heavy chain polypeptide of antibody sdr31.1-HC SEQ ID NO:76 and a light chain polypeptide of antibody ven31.1-LC SEQ ID NO:87;
cc) a heavy chain polypeptide of antibody ven31.1-HC SEQ ID NO:77 and alight chain polypeptide of antibody cdr31.1-LC SEQ ID NO:84;
dd) a heavy chain polypeptide of antibody ven31.1-HC SEQ ID NO:77 and a light chain polypeptide of antibody abb31.1-LC SEQ ID NO:85;
ee) a heavy chain polypeptide of antibody ven31.1-HC SEQ ID NO:77 and a light chain polypeptide of antibody sdr31.1-LC SEQ ID NO:86;
or
ff) a heavy chain polypeptide of antibody ven31.1-HC SEQ ID NO:77 and a light chain polypeptide of antibody ven31.1-LC SEQ ID NO:87.

30 more elements

Dependencies are inferred from the claim text.

Facts

Application: 16/874,826Filed 15 May 2020 · division
Priority: 28 Dec 2012
Published: US 2021/0002368 A17 Jan 2021
Granted: 22 Nov 2022
Term ends: Not estimatedThe source records don’t support an estimate.

Classification21 codes

C07K 16/2806
Against the immunoglobulin superfamily: against CD2
A61K 39/3955
Against materials from animals: against proteinaceous materials, e.g. enzymes, hormones, lymphokines
A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…
A61P 35/00
Antineoplastic agents

Family

Application61/747,067Us provisional application · filed 28 Dec 2012
PCT/US2013/078290Parent of this division · filed 30 Dec 2013
Application15/934,526Parent of this division · filed 23 Mar 2018
US 9,938,344 B2Parent of this division · filed 10 Apr 2018
US 2021/0002368 A1Pre-grant publication · published 7 Jan 2021
US 10,689,443 B2Parent of this division
Application14/655,982Parent of this division
US 2016/0194398 A1Published application
US 2018/0265583 A1Published application
US 11,505,604 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

An isolated nucleic acid that encodes an antibody or fragment thereof that binds to an A33 antigen, wherein said antibody or fragment thereof comprises:

a) a heavy chain comprising the variable chain of antibody cdr31.1-HC comprising amino acids 1 to 118 of SEQ ID NO:74 and a light chain comprising the variable light chain of antibody cdr31.1-LC comprising amino acids 1 to 107 of SEQ ID NO:84;
b) a heavy chain comprising the variable chain of antibody cdr31.1-HC comprising amino acids 1 to 118 of SEQ ID NO:74 and a light chain comprising the variable light chain of antibody abb31.1-LC comprising amino acids 1 to 107 of SEQ ID NO:85;
c) a heavy chain comprising the variable chain of antibody cdr31.1-HC comprising amino acids 1 to 118 of SEQ ID NO:74 and a light chain comprising the variable light chain of antibody sdr31.1-LC comprising amino acids 1 to 107 of SEQ ID NO:86;
d) a heavy chain comprising the variable chain of antibody cdr31.1-HC comprising amino acids 1 to 118 of SEQ ID NO:74 and a light chain comprising the variable light chain of antibody ven31.1-LC comprising amino acids 1 to 107 of SEQ ID NO:87;
e) a heavy chain comprising the variable chain of antibody abb31.1-HC comprising amino acids 1 to 118 of SEQ ID NO:75 and a light chain comprising the variable light chain of antibody cdr31.1-LC comprising amino acids 1 to 107 of SEQ ID NO:84;
f) a heavy chain comprising the variable chain of antibody abb31.1-HC comprising amino acids 1 to 118 of SEQ ID NO:75 and a light chain comprising the variable light chain of antibody abb31.1-LC comprising amino acids 1 to 107 of SEQ ID NO:85;
g) a heavy chain comprising the variable chain of antibody abb31.1-HC comprising amino acids 1 to 118 of SEQ ID NO:75 and a light chain comprising the variable light chain of antibody sdr31.1-LC comprising amino acids 1 to 107 of SEQ ID NO:86;
h) a heavy chain comprising the variable chain of antibody abb31.1-HC comprising amino acids 1 to 118 of SEQ ID NO:75 and a light chain comprising the variable light chain of antibody ven31.1-LC comprising amino acids 1 to 107 of SEQ ID NO:87;
i) a heavy chain comprising the variable chain of antibody sdr31.1-HC comprising amino acids 1 to 118 of SEQ ID NO:76 and a light chain comprising the variable light chain of antibody cdr31.1-LC comprising amino acids 1 to 107 of SEQ ID NO:84;
j) a heavy chain comprising the variable chain of antibody sdr31.1-HC comprising amino acids 1 to 118 of SEQ ID NO:76 and a light chain comprising the variable light chain of antibody abb31.1-LC comprising amino acids 1 to 107 of SEQ ID NO:85;
k) a heavy chain comprising the variable chain of antibody sdr31.1-HC comprising amino acids 1 to 118 of SEQ ID NO:76 and a light chain comprising the variable light chain of antibody sdr31.1-LC comprising amino acids 1 to 107 of SEQ ID NO:86;
l) a heavy chain comprising the variable chain of antibody sdr31.1-HC comprising amino acids 1 to 118 of SEQ ID NO:76 and a light chain comprising the variable light chain of antibody ven31.1-LC comprising amino acids 1 to 107 of SEQ ID NO:87;
m) a heavy chain comprising the variable chain of antibody ven31.1-HC comprising amino acids 1 to 118 of SEQ ID NO:77 and a light chain comprising the variable light chain of antibody cdr31.1-LC comprising amino acids 1 to 107 of SEQ ID NO:84;
n) a heavy chain comprising the variable chain of antibody ven31.1-HC comprising amino acids 1 to 118 of SEQ ID NO:77 and a light chain comprising the variable light chain of antibody abb31.1-LC comprising amino acids 1 to 107 of SEQ ID NO:85;
o) a heavy chain comprising the variable chain of antibody ven31.1-HC comprising amino acids 1 to 118 of SEQ ID NO:77 and a light chain comprising the variable light chain of antibody sdr31.1-LC comprising amino acids 1 to 107 of SEQ ID NO:86;
p) a heavy chain comprising the variable chain of antibody ven31.1-HC comprising amino acids 1 to 118 of SEQ ID NO:77 and a light chain comprising the variable light chain of antibody ven31.1-LC comprising amino acids 1 to 107 of SEQ ID NO:87;
q) a heavy chain polypeptide of antibody cdr31.1-HC SEQ ID NO:74 and a light chain polypeptide of antibody cdr31.1-LC SEQ ID NO:84;
r) a heavy chain polypeptide of antibody cdr31.1-HC SEQ ID NO:74 and a light chain polypeptide of antibody abb31.1-LC SEQ ID NO:85;
s) a heavy chain polypeptide of antibody cdr31.1-HC SEQ ID NO:74 and a light chain polypeptide of antibody sdr31.1-LC SEQ ID NO:86;
t) a heavy chain polypeptide of antibody cdr31.1-HC SEQ ID NO:74 and a light chain polypeptide of antibody ven31.1-LC SEQ ID NO:87;
u) a heavy chain polypeptide of antibody abb31.1-HC SEQ ID NO:75 and a light chain polypeptide of antibody cdr31.1-LC SEQ ID NO:84;
v) a heavy chain polypeptide of antibody abb31.1-HC SEQ ID NO:75 and a light chain polypeptide of antibody abb31.1-LC SEQ ID NO:85;
w) a heavy chain polypeptide of antibody abb31.1-HC SEQ ID NO:75 and a light chain polypeptide of antibody sdr31.1-LC SEQ ID NO:86;
x) a heavy chain polypeptide of antibody abb31.1-HC SEQ ID NO:75 and a light chain polypeptide of antibody ven31.1-LC SEQ ID NO:87;
y) a heavy chain polypeptide of antibody sdr31.1-HC SEQ ID NO:76 and a light chain polypeptide of antibody cdr31.1-LC SEQ ID NO:84;
z) a heavy chain polypeptide of antibody sdr31.1-HC SEQ ID NO:76 and a light chain polypeptide of antibody abb31.1-LC SEQ ID NO:85;
aa) a heavy chain polypeptide of antibody sdr31.1-HC SEQ ID NO:76 and a light chain polypeptide of antibody sdr31.1-LC SEQ ID NO:86;
bb) a heavy chain polypeptide of antibody sdr31.1-HC SEQ ID NO:76 and a light chain polypeptide of antibody ven31.1-LC SEQ ID NO:87;
cc) a heavy chain polypeptide of antibody ven31.1-HC SEQ ID NO:77 and alight chain polypeptide of antibody cdr31.1-LC SEQ ID NO:84;
dd) a heavy chain polypeptide of antibody ven31.1-HC SEQ ID NO:77 and a light chain polypeptide of antibody abb31.1-LC SEQ ID NO:85;
ee) a heavy chain polypeptide of antibody ven31.1-HC SEQ ID NO:77 and a light chain polypeptide of antibody sdr31.1-LC SEQ ID NO:86;
or
ff) a heavy chain polypeptide of antibody ven31.1-HC SEQ ID NO:77 and a light chain polypeptide of antibody ven31.1-LC SEQ ID NO:87.

30 more elements

Facts

Application

16/874,826Filed 15 May 2020 · division

Priority

28 Dec 2012

Published

US 2021/0002368 A17 Jan 2021

Granted

22 Nov 2022

Term ends

Not estimatedThe source records don’t support an estimate.

Classification21 codes

C07K 16/2806
Against the immunoglobulin superfamily: against CD2
A61K 39/3955
Against materials from animals: against proteinaceous materials, e.g. enzymes, hormones, lymphokines
A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…
A61P 35/00
Antineoplastic agents

Family

Application61/747,067Us provisional application · filed 28 Dec 2012

PCT/US2013/078290Parent of this division · filed 30 Dec 2013

Application15/934,526Parent of this division · filed 23 Mar 2018

US 9,938,344 B2Parent of this division · filed 10 Apr 2018

US 2021/0002368 A1Pre-grant publication · published 7 Jan 2021

US 10,689,443 B2Parent of this division

Application14/655,982Parent of this division

US 2016/0194398 A1Published application

US 2018/0265583 A1Published application

US 11,505,604 B2This patent

From the US filing history. Foreign family members aren’t listed.